Head-up tilt test – do we really know all about it?

Česká verzia

Authors: J. Plášek ¹; V. Do upal ²; Z. Hrabovská ¹
Authors place of work: Interní klinika FNsP Ostrava- Poruba, přednosta doc. MUDr. Arnošt Martínek, CSc. ¹; I. interní klinika Lékařské fakulty UP a FN Olomo uc, přednosta prof. MUDr. Jan Lukl, CSc. ²
Published in the journal: Vnitř Lék 2009; 55(10): 955-960
Category: Reviews

Summary

Head- up tilt test (HUTT) falls within the competence of functional cardiological examination. Most often it is being used for the diagnostical approach to possibly neurally- mediated syncope, less is known about the possibility of using tilt table test in the treatment of vasovagal syncope. The main goal of this article is to make clear the principles, appropriate indication, performance and subsumption of HUTT in the algorithm of syncope investigation. More over it will be marginally mentioned how HUTT can be used in predicting cardiovascular risk of patients with coronary artery disease.

Key words:
HUTT – vasovagal syncope – italian protocol – drug provocati ons – cardiovascular risk

Zdroje

1. Barón- Esquivi as G, Martínez-Rubio A. Tilt table test: state of the art. Indian Pacing Electrophysiol J 2003; 3: 239– 252.

2. Weissler AM, Warren JV, Estes EH jr et al. Vasodepressor syncope. Factors influencing cardiac o utput. Circulation 1957; 15: 875– 882.

3. Kenny RA, Ingram A, Bayliss J et al. Head up tilt: a useful test for investigating unexplained syncope. Lancet 1986; 1: 1352– 1355.

4. Siegelová J, Fišer B. Přístroj Task Force Monitor v diagnostice synkopy pomocí testu na nakloněné rovině. Vnitř Lék 2006; 52: 160– 166.

5. Semrád B. Klinické příznaky, diagnostika a terapi e ortostatické intolerance – editorial. Vnitř Lék 2006; 52: 113– 114.

6. Sutton R, Bloomfield DM. Indications, methodology, and classification of results of tilt- table testing. Am J Cardiol 1999; 84: 10Q– 19Q.

7. Burke SL, Dorward PK. Influence of endogenous opiates and cardiac afferents on renal nerve activity during haemorrhage in conscious rabbits. J Physiol 1988; 402: 9– 27.

8. Schadt JC, McKown MD, McKown DP et al. Hemodynamic effects of hemorrhage and subsequent naloxone treatment in conscious rabbits. Am J Physiol 1984; 247: R497– R505.

9. Wallbridge DR, MacIntyre HE, Gray CE et al. Role of endogenous opioids and catecholamines in vasovagal syncope. Eur Heart J 1996; 17: 1729– 1736.

10. Evans RG, Ludbrook J, Potocnik SJ. Intracisternal naloxone and cardiac nerve blockade prevent vasodilatation during simulated haemorhage in awake rabbits. J Physiol 1989; 409: 1– 14.

11. Fitzpatrick A, Williams T, Jeffrey C et al. Pathogenic role for argenine vasopresin (AVP) and catecholamines (EP NEP) in vasovagal syncope. J Am Coll Cardiol 1990; 15: 98A.

12. Fitzpatrick A, Williams T, Ahmed R et al. Echocardiographic and endocrine changes dutiny vasovagal syncope induced by prolonged head- up tilt. Eur H Cardiac Pacing Electrophysiol 1992; 2: 121– 128.

13. Lang CC, Struthers AD. Interactions between atrial natriuretic factor and the a utonomic nervous system. Clin Auton Res 1991; 1: 329– 336.

14. Flammang D, Luizy J, Wayneberger M. Re-initiation of the vasovagal syndrome by adenosine 5’triphosphate test assesment of the best therapy. Pacing Clin Electrophysiol 1990; 13: 539.

15. Nelson SD, Stanley M, Love CJ et al. The a utonomic and hemodynamic effects of oral theophylline in patients with vasodepressor syncope. Arch Intern Med 1991; 151: 2425– 2429.

16. Abboud FM. Neurocardiogenic syncope. N Engl J Med 1993; 328: 1117– 1120.

17. Grubb BP, Wolfe DA, Samoil D et al. Usefulness of fluoxetine hydrochloride for prevention of resistant upright tilt induced syncope. Pacing Clin Electrophysiol 1993; 16: 458– 464.

18. Alboni P, Bondanelli M, Dinelli M et al. Role of the serotoninergic system in the genesis of vasovagal syncope. Europace 2002; 2: 172– 180.

19. Mitro P, Hijova E, Mudrakova K. Role of the peripheral serotoninergic system in the pathogenesis of vasovagal syncope. Bratisl Lek Listy 2006; 107: 248– 252.

20. Rössler A, László Z, Haditsch B et al. Orthostatic stimuli rapidly change plasma adrenomedullin in humans. Hypertension 1999; 34: 1147– 1151.

21. Nishikimi T, Junichi M, Yasu T et al. Two molecular forms of plasma adrenomedullin during tilt test in healthy subjects. Peptides 2001; 22: 1867– 1872.

22. Bondanelli M, Alboni P, Margutti A et al. Plasma galanin response to head- up tilt in normal subjects and patients with recurrent vasovagal syncope. Metabolism 2003; 52: 315– 321.

23. Hinghofer- Szalkay HG, Rössler A, Evans JM et al. Circulatory galanin levels increase severalfold with intense orthostatic challenge in healthy humans. J Appl Physiol 2006; 100: 844– 849.

24. White CM, Tsikouris JP. A review of pathophysiology and therapy of patients with vasovagal syncope. Pharmacotherapy 2000; 20: 158– 165.

25. Alboni P, Alboni M, Bertorelle G. The origin of vasovagal syncope: to protect the heart or to escape predation? Clin Auton Res 2008; 18: 170– 178.

26. Diehl RR. Vasovagal syncope and Darwinian fitness. Clin Auton Res 2005; 15: 126– 129.

27. Alboni P, Brignole M, Degli Uberti EC. Is vasovagal syncope a disease? Europace 2007; 9: 83– 87.

28. Benditt DG, Ferguson DW, Grubb BP et al. Tilt table testing for assesing syncope. American College of Cardiology. J Am Coll Cardiol 1996; 28: 263– 275.

29. Brignole M, Alboni P, Benditt D et al. Task Force on Syncope, European Society of Cardiology. Guidelines on management (diagnosis and treatment) of syncope. Eur Hear J 2001; 22: 1256– 1306.

30. Brignole M, Alboni P, Benditt DG et al. Task Force on Syncope, European Society of Cardiology. Guidelines on management (diagnosis and treatment) of syncope- update 2004. Executive Summary. Eur Heart J 2004; 25: 2054– 2072.

31. Libby P, Bonow RO, Mann DL et al. Braunwald’s Heart disease. 8th ed. Philadelphia: Saunders Elsevi er 2008: 982– 983.

32. Fitzpatrick AP, Theodorakis G, Vardas P et al. Methodology of head- up tilt testing in patients with unexplained syncope. J Am Coll Cardiol 1991; 17: 125– 130.

33. Stein KM, Slotwiner DJ, Mittal S et al. Formal analysis of the optimal duration of tilt testing for the diagnosis of neurally mediated syncope. Am Heart J 2001; 141: 282– 288.

34. Almquist A, Goldenberg IF, Milstein S et al. Provocati on of bradycardia and hypotension by isoproterenol and upright posture in patients with unexplained syncope. N Engl J Med 1989; 320: 346– 351.

35. Kapoor WN, Brant N. Evaluati on of syncope by upright tilt testing with isoproterenol. A nonspecific test. Ann Intern Med 1992; 116: 358– 363.

36. Morillo CA, Klein GJ, Zandri S et al. Diagnostic accuracy of a low‑dose isoproterenol head- up tilt protocol. Am Heart J 1995; 129: 901– 906.

37. Natale A, Akhtar M, Jazayeri M et al. Provocati on of hypotension during head- up tilt testing in subjects with no history of syncope or presyncope. Circulation 1995; 92: 54– 58.

38. Raviele A, Gasparini G, Di Pede F et al. Nitroglycerin infusion during upright tilt: a new test for the diagnosis of vasovagal syncope. Am Heart J 1994; 127: 103– 111.

39. Raviele A, Menozzi C, Brignole M et al. Value of head- up tilt testing potentiated with sublingu al nitroglycerin to assess the origin of unexplained syncope. Am J Cardiol. 1995; 76: 267– 272.

40. Oraii S, Maleki M, Minoii M et al. Comparing two different protocols for tilt table testing sublingu al glyceryl nitrate versus isoprenaline infusions. Heart 1999; 81: 603– 605.

41. Raviele A, Giada F, Brignole M et al. Comparison of diagnostic accuracy of sublingu al nitroglycerin test and low‑dose isoproterenol test in patients with unexplained syncope. Am J Cardiol 2000; 85: 1194– 1198.

42. Del Rosso A, Bartoli P, Bartoletti A et al. Shortened head- up tilt testing potentiated with sublingu al nitroglycerin in patients with unexplained syncope. Am Heart J 1998; 135: 564– 570.

43. Natale A, Sra J, Akhtar M et al. Use of sublingual nitroglycerin during head- up tilt- table testing in patients > 60 years of age. Am J Cardiol 1998; 82: 1210– 1213.

44. Del Rosso A, Bartoletti A, Bartoli P et al. Methodology of head- up tilt testing potentiated with sublingual nitroglycerin in unexplained syncope. Am J Cardiol 2000; 85: 1007– 1011.

45. Voice RA, Lurie KG, Sakaguchi S et al. Comparison of tilt angles and provocative agents (edrophonium and isoproterenol) to improve head- upright tilt- table testing. Am J Cardiol 1998; 81: 346– 351.

46. Fisher JD, Kim SG, Ferrick KJ et al. Simplified tilt table test protocol with continuous upright position during medication administration and no hydration. Pacing Clin Electrophysiol 2003; 26: 451– 452.

47. Fitzpatrick AP, Lee RJ, Epstein LM et al. Effect of patient characteristics on the yield of prolonged baseline head- up tilt testing and the additi onal yield of drug provocation. Heart 1996; 76: 406– 411.

48. Theodorakis GN, Livanis EG, Leftheriotis H et al. Head- up tilt test with clomipramine challenge in vasovagal syndrome – a new tilt testing protocol. Eur Heart J 2003; 24: 658– 663.

49. Kirsch P, Mitro P, Mudrakova K et al. Diagnostic yield of adenosine and nitroglycerine stimulated tilt test in patients with unexplained syncope. Bratisl Lek Listy 2007; 108: 259– 264.

50. Benditt DG, Ferguson DW, Grubb BP et al. Tilt table testing for assessing syncope. American College of Cardiology. J Am Coll Cardiol 1996; 28: 263– 275.

51. McIntosh SJ, Lawson J, Kenny RA. Intravenous cannulation alters the specificity of head- up tilt testing for vasovagal syncope in elderly patients. Age Ageing 1994; 23: 317– 319.

52. Duygu H, Zoghi M, Turk U et al. The role of tilt training in preventing recurrent syncope in patients with vasovagal syncope: a prospective and randomized study. Pacing Clin Electrophysiol 2008; 31: 592– 596.

53. Reybrouck T, Ector H. Tilt training: a new challenge in the treatment of neurally mediated syncope. Acta Cardiol 2006; 61: 183– 189.

54. Müller H, Lerch R. Tilt table exercise echocardiography assessment in the diagnosis of coronary artery disease. Arch Cardiovasc Dis 2008; 101: 170– 174.

55. Hayano J, Mukai S, Fukuta H et al. Postural response of low- frequency component of heart rate variability is an increased risk for mortality in patients with coronary artery disease. Chest 2001; 120: 1942– 1952.

56. Ector H, Reybrouck T, Heidbüchel H et al. Tilt training: a new treatment for recurrent neurocardiogenic syncope and severe orthostatic intolerance. Pacing Clin Electrophysiol 1998; 21: 193– 196.

57. Foglia- Manzillo G, Giada F, Gaggioli G et al. Efficacy of tilt training in the treatment of neurally mediated syncope. A randomized study. Europace 2004; 6: 199– 204.

58. Doupal V, Lukl J. Vazovagální synkopa: Užití head- up tilt testu v její diagnostice a léčbě. In: Lukl J (ed). Srdeční arytmi e: Aktuální problémy. Praha: Grada Publishing 1996: 39– 55.

59. Vlašínová J. Algoritmus vyšetření při synkopě. Interní Med 2007; 9: 296– 298.

60. Doupal V, Lukl J. Head- up tilt test: jeho užití v diagnostice a léčbě vasovagální synkopy. Cor Vasa 1995; 37: 186.

61. Kautzner J. Synkopa: diagnostika a léčba. Cor Vasa 2007; 49 (Suppl): 63– 73.

62. Brignole M, Menozzi C, Del Rosso A et al. New classificati on of haemodynamics of vasovagal syncope: beyond the VASIS classificati on. Analysis of the pre‑syncopal phase of the tilt test without and with nitroglycerin challenge. Europace 2000; 2: 66– 76.